Innovation Pharmaceuticals Inc (IPIX)

[stevo99]

Interesting comparisons sox, though there are some significant differences. If Purisol can get good 2b results > 69%PASI then it should command leading market share in a $28.5 Billion/yr industry. I can't imagine BP wouldn't be willing to pony up a few billion if results are good.

1. Only 30% PASI at 700mg: "VTP-43742 demonstrated a clear signal of efficacy, with patients in the 350 mg dose group achieving a 24% reduction in the Psoriasis Area Severity Index (PASI) score relative to placebo. In the 700 mg dose group, patients achieved a 30% placebo-adjusted PASI score reduction."

2. Serious side affect with this one: "Wall Street gave Xenoport Inc. the hairy eyeball last September when data from the phase II trial hit the primary endpoint in psoriasis at both doses but turned up gastrointestinal (GI) side effects"

3. Very early, just finished a successful phase 1 trial: “Findings from this successful Phase 1 trial demonstrate that SNA-based drugs, such as AST-005, can regulate gene expression at the mRNA level in human skin."

4. Injectable, not oral but good results 69%PASI: "After nine months' treatment, 69% of moderate-to-severe plaque patients treated with the highest dose (180mg) of Boehringer's interleukin-23 inhibitor had clear or almost clear skin, compared to 30% of patients treated with J&J's Stelara (ustekinumab)"